106results about How to "Improve respiratory function" patented technology

An apparatus and method in which the portions of the labyrinth associated with the labyrinthine sense and / or the nerves associated therewith are stimulated to perform at least one of the following functions: augment or control a patient's respiratory function, open the patient's airway, induce sleep, and / or counteract vertigo. In one embodiment, the vestibular stimulating system of the present invention includes 1) a stimulation element that performs the actual stimulation of the tissue, 2) a sensor to detect a physiological condition of the patient, and 3) a power / control unit that receives the signals provided by the sensor and causes stimulation energy to be provided to the stimulation element at an appropriate timing, level, pattern, and / or frequency to achieve the desired function. However, the present invention also contemplates eliminating the sensor in favor of applying a predetermined pattern of stimulation to the patient.

An apparatus and method in which the portions of the labyrinth associated with the labyrinthine sense and / or the nerves associated therewith are stimulated to perform at least one of the following functions: augment or control a patient's respiratory function, open the patient's airway, induce sleep, and / or counteract vertigo. In one embodiment, the vestibular stimulating system of the present invention includes 1) a stimulation element that performs the actual stimulation of the tissue, 2) a sensor to detect a physiological condition of the patient, and 3) a power / control unit that receives the signals provided by the sensor and causes stimulation energy to be provided to the stimulation element at an appropriate timing, level, pattern, and / or frequency to achieve the desired function. However, the present invention also contemplates eliminating the sensor in favor of applying a predetermined pattern of stimulation to the patient.

An apparatus and method in which the portions of the labyrinth associated with the labyrinthine sense and / or the nerves associated therewith are stimulated to perform at least one of the following functions: augment or control a patient's respiratory function, open the patient's airway, induce sleep, and / or counteract vertigo. In one embodiment, the vestibular stimulating system of the present invention includes 1) a stimulation element that performs the actual stimulation of the tissue, 2) a sensor to detect a physiological condition of the patient, and 3) a power / control unit that receives the signals provided by the sensor and causes stimulation energy to be provided to the stimulation element at an appropriate timing, level, pattern, and / or frequency to achieve the desired function. However, the present invention also contemplates eliminating the sensor in favor of applying a predetermined pattern of stimulation to the patient.

The present invention provides a method for improving respiratory function and inhibiting muscular degeneration (e.g., dystrophy and atrophy). Alternative embodiments of the invention provide a method of inhibiting motor neuron apoptosis and the subsequent muscular degeneration associated with the denervation of muscular tissue resulting from neuron death.

The present invention relates to a compound represented by the formula (I),wherein all symbols are as defined in the description,a salt thereof, a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expected to be more effective than those of the leukotriene receptor antagonists currently used in clinical trials. Therefore, it is useful as an agent for the prevention and / or treatment of a leukotriene-mediated disease such as a respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g. interstitial pneumonia etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), or the like, or as an expectorant or an antiitussive.

A process for extracting cis-ligustilide includes such steps as pretreating, pulverizing, high-shear extracting, separating and purifying. Its advantages are low toxin and high output rate and purity. It can be used in preparing the medicine for prevent and treat the diseases associated with microcirculation disorder.

The invention discloses a human-body respiratory training device and a respiratory training feedback method. The human-body respiratory training device comprises a main control board and a portable device. The main control board comprises an air filtering and distributing module, a tidal volume detection module, a main control module, an inspiratory resistance increasing module and a communication module. A user breathes in air by holding the portable device, the breathed-in air is purified to be clean air through the air filtering and distributing module, the air is distributed into small-flow airflows, the tidal volume detection module detects the tidal volume in the small-flow airflows and converts the flowing-in airflow into electric signals, the main control module is used for collecting, detecting, analyzing and processing the electric signals, the inspiratory resistance increasing module is controlled to change inspiratory resistance according to the processed data, a peripheral structure of the portable device is used for reflecting the inspiratory resistance, and an operation display module can be used for regulating the strength and speed of inspiration and feeding back a training effect in real time. The human-body respiratory training device is simple in structure, convenient to carry, high in efficiency, low in cost, and high in practicability.

The present invention relates to a compound represented by the formula (I),wherein all symbols are as defined in the description,a salt thereof, a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expected to be more effective than those of the leukotriene receptor antagonists currently used in clinical trials. Therefore, it is useful as an agent for the prevention and / or treatment of a leukotriene-mediated disease such as a respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g. interstitial pneumonia etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), or the like, or as an expectorant or an antiitussive.

The present invention provides an auxiliary breathing apparatus including a balloon for covering a diaphragm portion of a human body and a pressure sensor for detecting the pressure of the abdomen during a breathing process, wherein the pressure sensor is connected to a controller, the balloon is connected to an air pump by an air channel and the air pump is used for inflating or deflating the balloon; and the air pump is connected with the controller. The auxiliary breathing apparatus can detect the abdominal pressure of a patient through the pressure sensor. When the patient exhales, the abdominal pressure reduces, the pressure sensor transmits a pressure signal to the controller, the controller controls the air pump to inflate the balloon, and the abdominal pressure is increased to promote the upward movement of the diaphragm ; and when the patient inhales, the abdominal pressure increases, the pressure sensor transmits a pressure signal to the controller, the controller controls the air pump to deflate the balloon, the abdominal pressure is reduced to promote the downward movement of the diaphragm. Therefore, in the process that the upward and downward movements of the diaphragm are promoted by the pressure of the balloon, the phrenic nerve is stimulated, the diaphragm function is enhanced, and the respiratory function of the patient improved.

Isolated nucleic acid-based vectors and lentivirus vectors, and methods of using those vectors to inhibit or prevent metabolic disorders in a mammal, are provided.

The invention discloses phosphogypsum putty powder prepared from phosphogypsum. The phosphogypsum putty powder is prepared from the following materials: 75-85% of a base material namely decolored phosphogypsum, 10-20% of a filler, 0.3-0.7% of a water retaining agent, 3-7% of a thickener and 0.1-0.5% of a retarder. According to the invention, the whiteness of phosphogypsum is first improved by a method of calcination and acid leaching, and the calcination temperature and the solid-liquid ratio of the method of calcination and acid leaching are determined. The whiteness of the decolored and whitened phosphogypsum can be increased from 25.0% to 80.0% or higher, the decolored phosphogypsum decolored and whitened through the method of calcination and acid leaching is used as the base material for the preparation of the putty powder, and by adding additives, the putty is modified in retarding, water tolerance, crack resistance and other aspects. By the above method, the invention can enablethe putty powder prepared by an industrial waste namely phosphogypsum to obtain the optimum modification effect. Physical properties of the obtained putty powder are in line with the requirements in JG / T298-2010 Putty for Interior.

The invention discloses a micro breathing machine which comprises a nose sealing support. A pair of micro eddy draught fans is installed at the positions, located on the nostrils, of the nose sealing support. Wind outlets of the micro eddy draught fans are formed in the opposite directions. Wind inlets face the front. A control panel is installed on the lower portion of the nose sealing support. A pressure sensor, a carbon dioxide sensor and an IC chip are installed on the control panel, wherein the IC chip controls the rotation number and the rotation direction of the micro eddy draught fans according to air parameters collected by the pressure sensor and the carbon dioxide sensor. The micro breathing machine further comprises a power source and a fixing mesh enclosure, wherein the power source supplies power to the micro eddy draught fans and the control panel and is installed on the upper portion of the nose sealing support, and the fixing mesh enclosure packages the parts and is detachably connected with the nose sealing support. Air inlets are formed in the positions, corresponding to the micro eddy draught fans, of the front of the fixing mesh enclosure, and exhaust openings are formed in the lower middle portion of the fixing mesh enclosure. The parts of the breathing machine are highly integrated, and therefore the breathing machine has the advantages of being small in size, convenient to carry, high in intelligence degree and capable of meeting needs of different people groups.

This invention is directed to substituted acylanilide compounds and uses thereof in treating muscular dystrophies such as Duchenne muscular dystrophy and Becker muscular dystrophy and in improving or preserving lung function and cardiac function in a subject suffering from Duchenne muscular dystrophy.

A device including a first flow channel, a second flow channel and a body part including an inner volume. A first space of the inner volume is adapted to be filled with liquid and a second space of the inner volume is arranged to receive steam. The device further includes means for conveying a gas flow from the steam space of the inner volume via the first flow channel to the outside of the device during inhalation and means for conveying the exhaled gas flow from the outside of the device via the second flow channel to the first space of the inner volume. The device further includes means for measuring a flow and a temperature of an airflow, and means for adjusting the flow of the airflow mechanically and / or automatically. The present disclosure further relates to a method and a system.

The invention relates to a clinical nutrition formula special for diseases of respiratory system. The clinical nutrition formula comprises protein, fat, carbohydrate, dietary fiber, macro-element, microelement, lipid-soluble vitamin, water soluble vitamin, diet essence, homologous medicinal and diet components, natural plant compound and new resource food. The invention also relates to a preparation method for the clinical nutrition formula. The method comprises the following steps: preparing all the components into powder in advance; performing alcohol extracting, water extracting, concentrating and spray-drying on the homologous medicinal and diet components, thereby acquiring powder; preparing the vitamins and fat into powder in the manner of microencapsulation treatment; or adopting a wet process for performing emulsifying, homogenizing and spray-drying on all the components, thereby acquiring the powder. Through the screening and matching of the components, the nutrition formula provided by the invention can supply comprehensive and sufficient nutrition support to the patient suffering from the diseases of respiratory system, so that the body immunity can be promoted, a certain effect for improving the nutrition state, respiratory function and life quality of the patient can be achieved and a better condition is established for treating the diseases.

The present invention relates to a compound of formula (I) (wherein all symbols have the same meanings as described hereinbefore). The compound antagonizes cysLT2 and therefore, it is useful as an agent for the prevention and / or treatment of respiratory diseases such as bronchial asthma, bronchial asthma, chronic obstructive pulmonary disease, pneumonectasia, chronic bronchitis, pneumonia (e.g. interstitial pneumonitis etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), and the like, or as an expectorant or antitussives.

There is provided a respiratory apparatus. The respiratory apparatus comprises a respiratory interface configured to aid a user in respiration and an attachment configured to hold the respiratory interface in position on the face of the user. The respiratory apparatus also comprises at least one electrode configured to provide electrical stimulation to one or more facial muscles of the user.

The composite medicine for treating respiratory system diseases is prepared with fritillary bulb, licorice, Chuanxiong rhizome, angelica, white mulberry bark, organe peel and other Chinese medicinal materials. It is used to treat acute and chronic tracheitis, bronchitis, bronchial pneumonia and other respiratory system diseases. It has the features of high curative effect, wide range of indications and low toxicity. Its preparation process includes crushing, distillation, digestion to extract, alcohol precipitation, packing, sterilization and other steps.

A medical paster for externally fixing the memory material and adhesive dressing in order to improve the respiratory function of lung and prevent complications is composed of an adhesive film paster, a dressing bag stuck on the central position of said film, a high-molecular memory material in said dressing bag, and a parting paper in the hollow square shape for surrounding said dressing bag. Its usage method is also disclosed.

Pharmaceutical compositions consisting essentially of: (a) an adrenergic complement; and (b) a pharmaceutically-acceptable carrier suitable for respiratory administration. Adrenergic complements include ascorbates, tocopherols, and polycarboxylic acid chelators. Methods are also provided for the treatment of respiratory disorders, particularly asthma.

A composition of nano-SOD and ginseng or its extract and its preparing process are disclose. It has high antioxidizing activity, high absorptivity and long half-life period, and can be used as the emergency medicine for sportsman, emergency patient, etc.

The present invention pertains to novel uses of glycyrrhetinic acid (GA), glycyrrhizic acid (GLA) and related compounds for prevention and / or treatment of pulmonary fibrosis, in particular, irradiation-induced pulmonary fibrosis. Also embodied are therapeutic uses of prodrugs, metabolites, derivatives (e.g., acids, esters and ethers), and salts of glycyrrhetinic acid (GA) and glycyrrhizic acid (GLA). The present invention also provides for therapeutic or pharmaceutical compositions comprising a compound of the invention in a form that can be combined with a pharmaceutically acceptable carrier.

The invention discloses an application of baicalein in preparation of drugs for preventing and / or treating diseases caused by novel coronavirus infection. Specifically, the invention relates to the application of the baicalein and a pharmaceutical composition containing baicalein in preparation of drugs for preventing and / or treating diseases caused by the novel coronavirus (SARS-CoV-2) infection, and the infectious diseases comprise mild, medium and severe infections caused by novel coronavirus, especially novel coronavirus pneumonia.

A ligustilide composition is prepared from ligustilide and medicinal plant oil through proportionally mixing, stirring, wrapping by lecithin microspheres or softgel, and preparing emulsion or capsule. Its medical application is also disclosed.

The present invention relates to a compound which is represented by the following general formula and has type 4 phosphodiesterase inhibitory action, and uses and an intermediate compound thereof.(whereinR1, R2: hydrogen, a halogen, a lower alkyl, a lower alkoxy, or the like,R3, R4: hydrogen, a (substituted) lower alkyl, a halogen, or the like,R5: hydrogen, a lower alkyl, a lower alkoxycarbonyl, or the like, andn: 0 or 1).

The invention discloses a traditional Chinese medicine preparation for treating the chronic bronchitis. Various crude medicines of the traditional Chinese medicine preparation comprise scutellaria baicalensis, cape jasmine fruits, platycodon grandiflorum, liquorice, rhizoma anemarrhenae, radix ophiopogonis, cortex mori, semen trichosanthis, orange peel, poria cocos, almonds, sea clam shells, bamboo juice, pinellia ternate, blackberry lily, houttuynia cordata, Chinese wax gourd seeds, coix seeds, thunberg fritillary bulbs, radix glehniae, asparagus cochinchinensis, pollen, roots of common diuranthera, corydalis pallida of mountain cang and litsea glutinosa remains. The traditional Chinese medicine preparation for treating the chronic bronchitis has the advantages that the preparation is capable of clearing heat, enabling lung qi to be purified and descend, eliminating phlegm and relieving a cough and mainly used for treating the phlegm-heat obstructing lungs, purifying and descending the lung qi, diminishing inflammation, relieving asthma and remarkably improving the respiratory function of the bronchus; the manufacturing technology is simple and convenient to operate, the toxic and side effect is small, the medicine administration is convenient, the preparation is easy to manufacture, cost is low, the preparation can reach the nidus directly, the cure time is short, and the chronic bronchitis is not prone to relapse once cured.

The invention discloses an oral solid self-emulsifying dispersoid for treating respiratory diseases of livestock and poultry. The oral solid self-emulsifying dispersoid is prepared from the followingactive pharmaceutical ingredients: 4 to 7 parts of volatile oil, 2 to 5 parts of emulsifying agents, 1 to 3 parts of co-emulsifying agents and 10 to 50 parts of solid dispersing agent carriers, wherein the volatile oil is prepared from fructus forsythiae oil, folium eucalypti oil, apricot kernel oil, radix platycodi oil and perilla seed oil through blending; the solid dispersing agent carriers arepolyethylene glycol. The pharmaceutical grade fructus forsythia oil, folium eucalypti oil, apricot kernel oil, radix platycodi oil and perilla seed oil are prepared into the volatile oil according toa certain proportion; the effective ingredients of the traditional Chinese medicine are fully utilized, and are combined with the emulsifying agents, the co-emulsifying agents and the solid dispersing agent carriers; the prepared finished product of the oral solid self-emulsifying dispersoid is pure natural and has no toxic and side effects; when the dispersoid is used for preventing and controlling the respiratory diseases of livestock and poultry, the stability of the volatile oil can be achieved; the medicine effect of the volatile oil is improved; the medicine resistance cannot occur; noresidue is left in livestock and poultry bodies; the harm to human bodies and environment is reduced; meanwhile, the production process is simple; the large-scale production is convenient.

The invention belongs to the field of medicine, and particularly relates to application of a Jinbei preparation in resisting coronavirus. The Jinbei preparation has inhibitory effects on the novel coronavirus (2019-nCoV) and SARS-CoV, can effectively inhibit the proliferation of 2019-nCoV and SARS-CoV in in vitro tests, has high therapeutic indexes for the 2019-nCoV and SARS-CoV, can reduce the degree of CPE lesions significantly and has good effects. The 15-day clinical observation results show that the Jinbei preparation is clinically effective in treating mild and common novel coronavirus pneumonia; the combined use of the Jinbei preparation and chemicals can shorten the time for patients with novel coronavirus pneumonia to turn negative, and the time for fatigue and cough to return tonormal, reduce patient temperature fluctuations during treatment and significantly shorten the effective days of treatment for patients with novel coronavirus pneumonia.